Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

EXACT Therapeutics

Mindre end 1K følgere

EXTX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Investorkonsensus

EXACT Therapeutics operates in the medical technology sector. The company specializes in the development of medical devices. The product portfolio is broad and includes, for example, technical platforms for drug testing. In addition to the main business, related ancillary services and value-added products are also offered. The business is operated globally with the largest presence in the Nordic market. The company was previously known as Phoenix Solutions and is headquartered in Oslo.

Læs mere
Markedsværdi
-
Aktieomsætning
-
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
13.3
2026

Ekstraordinær generalforsamling '26

8.4
2026

Årsrapport '25

12.6
2026

Generalforsamling '26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse3.3.2026, 13.15

EXACT Therapeutics - First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer

EXACT Therapeutics
Selskabsmeddelelse27.2.2026, 12.16

EXACT Therapeutics AS: Notice of extraordinary general meeting

EXACT Therapeutics
Selskabsmeddelelse27.2.2026, 07.54

EXACT Therapeutics AS: Warrants exercise

EXACT Therapeutics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse12.2.2026, 09.48

EXTX: Financial calendar

EXACT Therapeutics
Selskabsmeddelelse11.2.2026, 07.00

EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program

EXACT Therapeutics
Selskabsmeddelelse6.2.2026, 07.30

EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program

EXACT Therapeutics
Selskabsmeddelelse5.2.2026, 12.19

EXACT Therapeutics: Correction of final warrants exercise date

EXACT Therapeutics
Selskabsmeddelelse5.2.2026, 08.17

EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders

EXACT Therapeutics
Selskabsmeddelelse5.2.2026, 07.30

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

EXACT Therapeutics
Selskabsmeddelelse27.1.2026, 07.00

EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants

EXACT Therapeutics
Selskabsmeddelelse8.1.2026, 07.30

EXTX: EXACT Therapeutics' Phase 2 trial in pancreatic cancer patients to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium

EXACT Therapeutics
Selskabsmeddelelse25.11.2025, 11.57

EXTX: EXACT Therapeutics to present company update

EXACT Therapeutics
Selskabsmeddelelse24.11.2025, 07.25

EXACT Therapeutics AS: New option program and receipt of share options by primary insiders

EXACT Therapeutics
Selskabsmeddelelse25.9.2025, 06.00

EXTX: EXACT Therapeutics first half 2025 interim results

EXACT Therapeutics
Selskabsmeddelelse18.9.2025, 06.00

EXTX: EXACT Therapeutics' Phase 2 trial to be presented at the 2025 AACR Special Conference

EXACT Therapeutics
Selskabsmeddelelse9.9.2025, 06.00

EXTX: EXACT Therapeutic's Acoustic Cluster Therapy to be presented at the Ninth International Cancer lmmunotherapy Conference

EXACT Therapeutics
Selskabsmeddelelse12.8.2025, 06.30

EXTX: EXACT Therapeutics to Present at the European Society for Medical Oncology (ESMO) Congress 2025

EXACT Therapeutics
Selskabsmeddelelse11.8.2025, 09.08

EXTX: Financial calendar

EXACT Therapeutics
Selskabsmeddelelse8.7.2025, 06.30

EXTX: EXACT Therapeutics announces grant of core patent in the U.S.

EXACT Therapeutics
Selskabsmeddelelse24.6.2025, 06.00

EXTX: EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

EXACT Therapeutics
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.